Cabaletta Bio to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotech company, will have CEO Steven Nichtberger participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 11:00 a.m. ET in Miami, FL. This event will highlight the company's focus on developing targeted cell therapies for autoimmune diseases. Interested individuals can access a live webcast on the company's website, with replays available for 30 days after the event.

PHILADELPHIA, May 17, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 11:00 a.m. ET in Miami, FL.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform, in combination with Cabaletta Bio’s proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with FVIII alloantibodies. Cabaletta Bio’s headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and follow us on LinkedIn.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com

FAQ

When is Cabaletta Bio's CEO speaking at the H.C. Wainwright Global Investment Conference?

Steven Nichtberger, CEO of Cabaletta Bio, will speak at the conference on May 24, 2022, at 11:00 a.m. ET.

Where can I watch the Cabaletta Bio presentation live?

The live webcast of Cabaletta Bio's presentation can be viewed on their official website.

What is Cabaletta Bio focused on?

Cabaletta Bio is focused on discovering and developing targeted cell therapies for autoimmune diseases.

What are some potential treatments being developed by Cabaletta Bio?

Cabaletta Bio is developing treatments for conditions including mucosal pemphigus vulgaris and MuSK-associated myasthenia gravis.

How long will the replay of Cabaletta Bio's presentation be available?

The replay will be available on Cabaletta Bio's website for 30 days after the presentation.